Pfizer pill cuts risk of severe COVID-19 by 89%
Image Credit: NewsBytes
American company Pfizer's experimental antiviral pill to treat COVID-19 cuts the risk of hospitalization and death by 89% in vulnerable adults, according to clinical trial results. The firm said it has stopped trials early as the initial results were so favorable. The results are seemingly better than those seen with Merck & Co. Inc.'s pill, molnupiravir.